Literature DB >> 28776579

Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.

Melike Pekmezci1, Areli K Cuevas-Ocampo1, Arie Perry1,2, Andrew E Horvai1.   

Abstract

The diagnosis of malignant peripheral nerve sheath tumors can be challenging and other spindle cell sarcomas commonly enter in the differential diagnosis. Loss of trimethylation at lysine 27 of histone-H3 (H3K27me3) by immunohistochemistry was recently described in malignant peripheral nerve sheath tumors. However, its specificity remains controversial. We therefore studied 82 synovial sarcomas, 39 malignant peripheral nerve sheath tumors, and 10 fibrosarcomatous dermatofibrosarcoma protuberans for H3K27me3 loss by immunohistochemistry. The diagnoses were based on morphology, immunophenotype, and genetics based on WHO classification. H3K27me3 immunohistochemistry was scored by two pathologists based on fraction of cells with nuclear staining (score 0 to 3+). Loss of H3K27me3 (score 0) was seen in 44% of malignant peripheral nerve sheath tumors and 9% of synovial sarcomas yielding positive and negative predictive values of 71% and 77%, respectively. Loss of H3K27me3 was seen in 10% of fibrosarcomatous dermatofibrosarcoma protuberans, yielding positive and negative predictive values of 94 and 29% in the differential diagnosis of malignant peripheral nerve sheath tumor versus fibrosarcomatous dermatofibrosarcoma protuberans. Partial loss (score 1-2) was common in all three tumor types. Among malignant peripheral nerve sheath tumors, there was no significant association between H3K27me3 loss and gender, tumor site, or size, and progression-free or overall survival. Patients with tumors with H3K27me3 loss were younger than those with tumors with retained H3K27me3 expression (P=0.011). H3K27me3 expression was lost in 50 and 31% of sporadic and Neurofibromatosis-associated malignant peripheral nerve sheath tumors, respectively (P=0.25).Complete H3K27me3 loss is a moderately sensitive and relatively specific marker for the diagnosis of malignant peripheral nerve sheath tumor when the differential diagnosis includes synovial sarcoma and fibrosarcomatous dermatofibrosarcoma protuberans. Partial loss has limited diagnostic utility. H3K27me3 status does not show significant association with clinical outcome in malignant peripheral nerve sheath tumors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28776579     DOI: 10.1038/modpathol.2017.97

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

2.  Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Authors:  Melike Pekmezci; David E Reuss; Angela C Hirbe; Sonika Dahiya; David H Gutmann; Andreas von Deimling; Andrew E Horvai; Arie Perry
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

3.  Methylation-based classification of benign and malignant peripheral nerve sheath tumors.

Authors:  Manuel Röhrich; Christian Koelsche; Daniel Schrimpf; David Capper; Felix Sahm; Annekathrin Kratz; Jana Reuss; Volker Hovestadt; David T W Jones; Melanie Bewerunge-Hudler; Albert Becker; Joachim Weis; Christian Mawrin; Michel Mittelbronn; Arie Perry; Victor-Felix Mautner; Gunhild Mechtersheimer; Christian Hartmann; Ali Fuat Okuducu; Mirko Arp; Marcel Seiz-Rosenhagen; Daniel Hänggi; Stefanie Heim; Werner Paulus; Jens Schittenhelm; Rezvan Ahmadi; Christel Herold-Mende; Andreas Unterberg; Stefan M Pfister; Andreas von Deimling; David E Reuss
Journal:  Acta Neuropathol       Date:  2016-02-08       Impact factor: 17.088

4.  Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study.

Authors:  Andrew E Horvai; Miranda J Kramer; Richard O'Donnell
Journal:  Arch Pathol Lab Med       Date:  2006-06       Impact factor: 5.534

5.  Sox10 and S100 in the diagnosis of soft-tissue neoplasms.

Authors:  Jason R Karamchandani; Torsten O Nielsen; Matt van de Rijn; Robert B West
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-10

6.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

7.  Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma.

Authors:  Yuna Kang; Melike Pekmezci; Andrew L Folpe; Ayca Ersen; Andrew E Horvai
Journal:  Mod Pathol       Date:  2013-08-09       Impact factor: 7.842

8.  Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.

Authors:  Carlos N Prieto-Granada; Thomas Wiesner; Jane L Messina; Achim A Jungbluth; Ping Chi; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

9.  Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Authors:  Yi-Che Changchien; Péter Tátrai; Gergő Papp; Johanna Sápi; László Fónyad; Miklós Szendrői; Zsuzsanna Pápai; Zoltán Sápi
Journal:  J Transl Med       Date:  2012-10-30       Impact factor: 5.531

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  14 in total

1.  HYPERsol: High-Quality Data from Archival FFPE Tissue for Clinical Proteomics.

Authors:  Dylan M Marchione; Ilyana Ilieva; Kyle Devins; Danielle Sharpe; Darryl J Pappin; Benjamin A Garcia; John P Wilson; John B Wojcik
Journal:  J Proteome Res       Date:  2020-01-14       Impact factor: 4.466

Review 2.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

3.  CDX2 expression in malignant peripheral nerve sheath tumour: a potential diagnostic pitfall associated with PRC2 inactivation.

Authors:  Olumide O Odeyemi; Michael G Ozawa; Gregory W Charville
Journal:  Histopathology       Date:  2022-02-28       Impact factor: 7.778

Review 4.  Soft Tissue Special Issue: Biphenotypic Sinonasal Sarcoma: A Review with Emphasis on Differential Diagnosis.

Authors:  John Gross; Karen Fritchie
Journal:  Head Neck Pathol       Date:  2020-01-16

5.  Polycomb repression regulates Schwann cell proliferation and axon regeneration after nerve injury.

Authors:  Ki H Ma; Phu Duong; John J Moran; Nabil Junaidi; John Svaren
Journal:  Glia       Date:  2018-10-11       Impact factor: 7.452

6.  Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall.

Authors:  Xiang Xu; Doreen Palsgrove; Elizabeth Kurian; Shirley Yan; Bahram R Oliai; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-04-01

7.  Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.

Authors:  Calixto-Hope G Lucas; Harish N Vasudevan; William C Chen; Stephen T Magill; Steve E Braunstein; Line Jacques; Sonika Dahiya; Fausto J Rodriguez; Andrew E Horvai; Arie Perry; Melike Pekmezci; David R Raleigh
Journal:  Neurooncol Adv       Date:  2020-10-01

8.  Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.

Authors:  Ratnakar Singh; Zeeshan Fazal; Andrea K Corbet; Emmanuel Bikorimana; Jennifer C Rodriguez; Ema M Khan; Khadeeja Shahid; Sarah J Freemantle; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

Review 9.  H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.

Authors:  Marta Hałasa; Anna Wawruszak; Alicja Przybyszewska; Anna Jaruga; Małgorzata Guz; Joanna Kałafut; Andrzej Stepulak; Marek Cybulski
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

10.  Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Authors:  Fausto J Rodriguez; Mindy K Graham; Jacqueline A Brosnan-Cashman; John R Barber; Christine Davis; M Adelita Vizcaino; Doreen N Palsgrove; Caterina Giannini; Melike Pekmezci; Sonika Dahiya; Murat Gokden; Michael Noë; Laura D Wood; Christine A Pratilas; Carol D Morris; Allan Belzberg; Jaishri Blakeley; Christopher M Heaphy
Journal:  Acta Neuropathol Commun       Date:  2019-08-28       Impact factor: 7.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.